Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Volume 1852, Issue 12, Pages 2706-2711Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbadis.2015.09.022
Keywords
RAGE; S100 proteins; Pancreatic ductal adenocarcinoma
Funding
- Pilot Project Award at the Center for Protease Research (NIH-COBRE grant) [5P30GM103332]
- College of Health Professions at North Dakota State University
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with low survival rates. Current therapeutic treatments have very poor response rates due to the high inherent chemoresistance of the pancreatic-cancer cells. Recent studies have suggested that the receptor for advanced glycation end products (RAGE) and its S100 protein ligands play important roles in the progression of PDAC. We will discuss the potential role of S100 proteins and their receptor, RAGE, in the development and progression of pancreatic cancer. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
